Kazia is making good progress with its two pipeline assets, paxalisib and EVT801, with the latter having cleared third dose level and is recruiting well.
The company also notes the GBM AGILE pivotal study has opened in France, the fourth country to start recruitment to the paxalisib arm.
“Positive data” is being presented regarding the activity of Kazia's lead drug paxalisib in two forms of childhood brain cancers.
The company is presenting the data via two presentations this week at the 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) in Germany.
Dr James Garner provides an update on the oncology company's lead program, a glioblastoma treatment candidate known as paxalisib.
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Which of the following group do you best fit?
Subscribe to our Email Alerts